32 Recruiting Solid Tumor, Adult Phase 1 Clinical Trials
Active phase 1 studies for solid tumor, adult enrolling across the USA. Verify eligibility and contact site coordinators.
All Solid Tumor, Adult studiesPhase 1 Studies for Solid Tumor, Adult
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
📍 Florida Cancer Specialists — Sarasota, Florida
View Study & Checklist ➔First-in-Human Study of ICT01 in Patients With Advanced Cancer
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
📍 UCLA Hematology/Oncology — Los Angeles, California
View Study & Checklist ➔Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
📍 Cedars-Sinai Medical Center — Los Angeles, California
View Study & Checklist ➔A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
📍 Honor Health — Scottsdale, Arizona
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
📍 Banner Health — Gilbert, Arizona
View Study & Checklist ➔A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
📍 Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View Study & Checklist ➔Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
📍 Sarcoma Oncology Research Center — Santa Monica, California
View Study & Checklist ➔Advanced or Recurrent Solid Tumors Treated With SHetA2
📍 Stephenson Cancer Center — Oklahoma City, Oklahoma
View Study & Checklist ➔A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
📍 The Angeles Clinic — Los Angeles, California
View Study & Checklist ➔Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔Study to Evaluate D-1553 in Subjects With Solid Tumors
📍 Research Site — Fresno, California
View Study & Checklist ➔A Monotherapy in Subjects With Advanced Solid Tumors
📍 Sarcoma Oncolog Research Center — Santa Monica, California
View Study & Checklist ➔Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors
📍 University of Southern California- Norris Cancer Center — Los Angeles, California
View Study & Checklist ➔A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
📍 University of California Los Angeles — Los Angeles, California
View Study & Checklist ➔Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
📍 UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
View Study & Checklist ➔Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
📍 HonorHealth Research Institute — Scottsdale, Arizona
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
📍 Henry Ford Cancer Institute — Detroit, Michigan
View Study & Checklist ➔First In Human Study of CX-2051 in Advanced Solid Tumors
📍 Sarah Cannon Research Institute at HealthONE — Denver, Colorado
View Study & Checklist ➔A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
📍 Site USA12-0 — Los Angeles, California
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
📍 Banner Health — Gilbert, Arizona
View Study & Checklist ➔Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
📍 UCLA — Santa Monica, California
View Study & Checklist ➔BP1001-A in Patients With Advanced or Recurrent Solid Tumors
📍 Holy Cross Hospital — Silver Spring, Maryland
View Study & Checklist ➔R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
📍 Sarah Cannon Research Institute — Nashville, Tennessee
View Study & Checklist ➔A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
📍 O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of VET3-TGI in Patients With Solid Tumors
📍 USC/Norris Comprehensive Cancer Center — Los Angeles, California
View Study & Checklist ➔First In Human Study of CX-801 in Advanced Solid Tumors
📍 The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate — Los Angeles, California
View Study & Checklist ➔ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
📍 Chao Family Comprehensive Cancer Center, University of California, Irvine — Orange, California
View Study & Checklist ➔A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
📍 The Angeles Clinic and Research Institute — Los Angeles, California
View Study & Checklist ➔Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
View Study & Checklist ➔